Email Drip Series #2 – Moskowitz Report 2

Want proof? Silicon Valley billionaires have already invested over a half billion dollars to get it launched!

It’s going to be transformative and you can still get on board…while this trend is forming!

Biotech trends like this can be significant for early investors…and nothing drives a trend harder and faster than smart money pumping fuel to a launch.

You saw that when astute investors poured billions of dollars into companies that launched research initiatives into the medical potential of cannabinoid compounds. Many early investors have made significant returns from the progress that has been made in this sector.

We are now entering Phase Two of a pharmaceutical renaissance. Emerging biotechs are researching once forbidden drugs to solve some of the most vexing medical problems. Early entries have already posted staggering profits…and this trend is just getting started!

My calculations reveal the market for psychotropic drug therapies could grow many times faster than what investors anticipated from the recreational marijuana market.

And it’s just the start of what is looking to be a significant trend.

New research into these organically-derived pharmaceutical compounds has triggered a revolution in promising new therapies. Much of this focuses on diseases and injuries to the brain.

Findings are that once-forbidden compounds such as psilocybin, LSD, ketamine, ibogaine and others hold significant promise for treating, even curing mental disorders and injuries once thought to be incurable. Legal restrictions formerly kept these compounds out of the lab, their benefits remained clouded in secrecy. Now those secrets are coming to light and it appears clear to many that was a HUGE missed opportunity.

Has the government finally recognized its decades-old error in judgment?

It appears so. Politicians are now following the science…even the U.S. military is getting involved.

The Pentagon already invested $26.9 million backing² research that advances the use of medical psychedelic compounds in mental health therapy.

The real sign that this sector is gaining scientific interest came when the FDA assigned “fast track” designation for a new class of organically derived medical psychedelic compounds for treatment resistant depression. With fast-track designation, candidate drugs move through the approval process much faster than usual. New drugs can be released to market more quickly that way.

These are very important pharmaceutical developments that could change the lives for millions! That’s not all.

The pharmaceutical value of this approach is building fast…likely worth billions over the course of a decade.⁴ And it doesn’t end there.

CLICK HERE TO READ THE FULL REPORT ON THIS POTENTIALLY REVOLUTIONARY OPPORTUNITY